BioNTech/Pfizer Begins Testing an Omicron-Specific COVID-19 Vaccine

January 26, 2022

In a new clinical trial announced yesterday, Pfizer and BioNTech have begun a clinical trial to evaluate a new, omicron-specific vaccine for COVID-19. Even though people who are vaccinated and boosted appear to be better protected against severe COVID symptoms and hospitalization from omicron, the new highly contagious variant has still led to breakthrough cases and a surge in overall infections across the world. The study will include over 1,000 participants.

Kathrin U. Jansen, Pfizer’s senior vice president and head of vaccine research and development stated: “While current research and real-world data show that boosters continue to provide a high level of protection against severe disease and hospitalization with Omicron, we recognize the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future.”

Source: NPR

Similar Articles